Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cue Biopharma, Inc.NASDAQ: CUE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $48K fell 96.4% year over year, behind the -44.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 92.1% from the prior quarter. Over 3 fiscal years it compounded at -20.7% a year.

Context

  • Stock-based compensation amounted to 17.3% of revenue in FY2025, down 56.4 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -96.4% toward the trailing-twelve-month pace of -44.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48K-92.1% QoQ
Last fiscal yearDec 2025
$4.74M-30.7% YoY
LTMMar 2026
$3.45M-44.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.4%——
1 year-30.7%——
3-year CAGR-20.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
4.74M USD
Year-over-year change
-30.7%
4-year CAGR
-19.9%

Stock-Based Compensation vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 stock-based compensation of $3.45M is the 3rd largest of the 7 companies compared; the peer median is $2.68M.
  • Its year-over-year change of -44.6% is the 6th highest of 7, against a peer median of -29.9%.
  • Stock-based compensation amounts to 10.6% of revenue for CUE, versus a peer median of 128.8%.
CUE Competitors Peer median
Stock-Based Compensation for CUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M -50.8%-13.8%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M -37.3%+4.9%1543.3%
CUECue Biopharma, Inc.LTM Mar 2026$3.45M -44.6%-20.7%10.6%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$2.72M -37.2%-10.8%—
EQEquillium, Inc.LTM Mar 2026$2.63M -22.6%-21.7%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.82M +13.4%—128.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$367K +43.4%-60.2%16.0%
Peer median (excluding CUE) $2.68M-29.9%-13.8%128.8%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Depreciation & Amortization(1.78M)1.81M3.44M2.35M958K
Deferred Income Tax00000
Stock-Based Compensation11.52M9.5M8.18M6.85M4.74M
Change in Working Capital(4.39M)356K(934K)(4.93M)(3.3M)
Accounts Receivables(1.73M)3.09M(1.64M)753K(6.5M)
Inventory00000
Accounts Payables520.4K83K770K(678K)1.13M
Other Working Capital(3.18M)(2.81M)(63K)(5M)2.08M
Other Non-Cash Items(26.13K)(454K)90K74K2.51M
Operating Cash Flow(38.84M)(41.81M)(39.96M)(36.33M)(21.69M)
Capital Expenditures(913.04K)(171K)0(66K)(177K)
Acquisitions (Net)000040K
Purchases of Investments0(29.45M)00(16.5M)
Sales of Investments10M5M25M016.5M
Other Investing Activities21.55K6K2K98K212K
Investing Cash Flow9.11M(24.61M)25M32K75K
Debt Repayment010M(2M)(4M)(4.5M)
Common Stock Issued17.38M39.3M13.39M14.22M30.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M4.36M473K18K0
Financing Cash Flow19.23M53.66M11.86M10.24M26.29M
Effect of Forex Changes00000
Net Change in Cash(10.5M)(12.76M)(3.1M)(26.05M)4.68M
Free Cash Flow(39.75M)(41.98M)(39.96M)(36.4M)(21.86M)

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.